NorthStrive expands AI program with Yuva to nominate cardiac leads
NorthStrive Biosciences has executed a First Amendment to its Development and License Agreement with Yuva Biosciences to launch a three-phase Expansion Program that will advance four AI-discovered small-molecule compounds toward lead nomination for potential cardiac disease and obesity therapeutics.
<p>NorthStrive Biosciences has executed a First Amendment to its Development and License Agreement with Yuva Biosciences to launch a three-phase Expansion Program that will advance four AI-discovered small-molecule compounds toward lead nomination for potential cardiac disease and obesity therapeutics.</p>